title: Molecular Pharming: future targets and aspirations.
abstract: Molecular Pharming represents an unprecedented opportunity to manufacture affordable modern medicines and make these available at a global scale. The area of greatest potential is in the prevention of infectious diseases, particular in underdeveloped countries where access to medicines and vaccines has historically been limited. This is why, at St. George's, we focus on diseases such as HIV, TB and rabies, and aim to develop production strategies that are simple and potentially easy to transfer to developing countries.
authors.affiliation: Molecular Immunology Unit, Research Centre for Infection and Immunity, St. George's Hospital Medical School, London, UK.
authors.forename: Mathew
authors.initials: M
authors.lastname: Paul
authors.forename: Craig
authors.initials: C
authors.lastname: van Dolleweerd
authors.forename: Pascal M W
authors.initials: PM
authors.lastname: Drake
authors.forename: Rajko
authors.initials: R
authors.lastname: Reljic
authors.forename: Harry
authors.initials: H
authors.lastname: Thangaraj
authors.forename: Tommaso
authors.initials: T
authors.lastname: Barbi
authors.forename: Elena
authors.initials: E
authors.lastname: Stylianou
authors.forename: Ilaria
authors.initials: I
authors.lastname: Pepponi
authors.forename: Leonard
authors.initials: L
authors.lastname: Both
authors.forename: Verena
authors.initials: V
authors.lastname: Hehle
authors.forename: Luisa
authors.initials: L
authors.lastname: Madeira
authors.forename: Varghese
authors.initials: V
authors.lastname: Inchakalody
authors.forename: Sammy
authors.initials: S
authors.lastname: Ho
authors.forename: Thais
authors.initials: T
authors.lastname: Guerra
authors.forename: Julian K-C
authors.initials: JK
authors.lastname: Ma
mesh_terms: D016915:AIDS Vaccines / Q000096:biosynthesis; D000276:Adjuvants, Immunologic / Q000096:biosynthesis; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D000936:Antigen-Antibody Complex / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D003906:Developing Countries; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D018527:Hydroponics; D018973:Intellectual Property; D051379:Mice; D058634:Molecular Farming / Q000379:methods*; D063245:Plant Development; D030821:Plants, Genetically Modified / Q000254:growth & development; D011819:Rabies Vaccines / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D018581:Technology Transfer; D032581:Tuberculosis Vaccines / Q000096:biosynthesis; D014612:Vaccines / Q000096:biosynthesis*
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D011819:Rabies Vaccines; D011994:Recombinant Proteins; D032581:Tuberculosis Vaccines; D014612:Vaccines